Developing first-in-class therapeutics against the most impactful cancer targets
Vortex Therapeutics is a drug discovery and development company focused on developing small-molecule inhibitors of intrinsically disordered proteins to bring new medicines to cancer patients. The company is developing first-in-class therapeutics against the most impactful cancer targets, with a specific focus on novel mechanisms of action targeting emergent oncogenic pathways. Co-founded by Gary Schiltz, a Research Professor at Northwestern University, Vortex Therapeutics leverages over 20 years of pharmaceutical and clinical experience to advance its oncology pipeline.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountNo funding data available yet.
Know something? Help us improve our data.
Create a free account to see which investors have funded this company.
Create Free Account
